ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



Alina Robert, MD, FACC Chapter President

Robert Duerr, MD, FACC Incoming Governor

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk
    Cardiovascular-kidney-metabolic (CKM) syndrome is associated with incremental cancer risk and stage-specific immune-metabolic pathways, according to a study using data from the UK Biobank published July 16 in JACC: CardioOncology. These findings highlight potential prevention targets.
  • If You Build It, Will They Come? Digital Health in AF Management
    Atrial fibrillation (AF) is the most common sustained arrhythmia in the United States, with a nation-wide prevalence projected to reach 12.1 million by 2030.1 AF is a major driver of adverse clinical outcomes, including stroke, dementia, myocardial infarction, sudden cardiac death, heart failure, chronic kidney disease, and all-cause death.
  • ACC CardiaCast: Beyond the Kidneys: UACR and Cardiovascular Risk
    Dr. Ankeet Bhatt interviews Dr. Nihar Desai on key terminology for albuminuria and discuss CV conditions associated with UACR as a biomarker.
  • Updated ACC Expert Consensus Decision Pathway Addresses Management of HFpEF
    The updated 2026 ACC Expert Consensus Decision Pathway (ECDP) for the Management of Heart Failure With Preserved Ejection Fraction (HFpEF) reflects a significant evolution in how HFpEF is understood and treated.
  • DAPT-MVD: Extended DAPT Cuts CV Events After PCI in Multivessel CAD
    Extending DAPT for an additional year reduced major adverse cardiovascular events (MACE) without increasing bleeding risk compared with aspirin alone among patients with multivessel coronary artery disease (MVCAD) who had no ischemic or bleeding events one year after PCI with a drug-eluting stent, according to results of the DAPT-MVD trial published July 15 in NEJM.